In a postmenopausal woman with an enlarged ovary on transabdominal ultrasound, what is the clinical significance and how should serum CA‑125 and CEA be utilized?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Enlarged Ovary in Postmenopausal Women: Clinical Significance and Role of Tumor Markers

An enlarged ovary in a postmenopausal woman is highly concerning for malignancy and requires immediate further evaluation with transvaginal ultrasound with Doppler, followed by CA-125 measurement—but CA-125 should NOT be used alone to rule out malignancy, as it performs worse than ultrasound imaging in distinguishing benign from malignant lesions.

Clinical Significance

The finding of an enlarged ovary on transabdominal ultrasound in a postmenopausal woman carries significant malignancy risk. Normal postmenopausal ovaries should be small and often non-palpable. Any enlargement warrants concern, though the specific ultrasound characteristics determine the actual risk level.

Immediate Next Steps

You must obtain transvaginal ultrasound with color/power Doppler imaging 1. Transabdominal ultrasound alone is insufficient for risk stratification. The transvaginal approach provides superior characterization of:

  • Morphologic features: Simple cyst vs. complex cystic vs. solid components
  • Presence of papillary projections or solid nodules
  • Septal characteristics (thin <3mm vs. thick)
  • Vascularity patterns using Doppler to identify neovascularity in solid components

Risk Stratification Using O-RADS

Apply the O-RADS US classification system to categorize malignancy risk 2:

  • O-RADS 1-2: Physiologic or benign findings (0-10% malignancy risk)
  • O-RADS 3: Low risk (1-10%)
  • O-RADS 4: Intermediate risk (10-50%)
  • O-RADS 5: High risk (50-100%)

Critical point: Simple cysts in postmenopausal women are benign in 100% of cases 1. However, any complex features elevate concern significantly.

Role of CA-125: Use With Caution

Key Evidence on CA-125 Limitations

CA-125 alone performs WORSE than ultrasound in distinguishing benign from malignant ovarian lesions 1. The O-RADS committee deliberately excluded routine tumor marker use from their risk stratification system because 2:

  • False reassurance risk: A normal CA-125 may provide false reassurance in a postmenopausal woman with an intermediate- or high-risk (O-RADS 4 or 5) lesion
  • Limited sensitivity: CA-125 may be low in borderline tumors, low-grade malignancies, and mucinous carcinomas
  • Context-dependent utility: CA-125 improves specificity ONLY in lesions already suspected to be malignant on ultrasound 1

When CA-125 IS Useful

Measure CA-125 in postmenopausal women when ultrasound shows suspicious features 3, 4, 5:

  • Optimal threshold: CA-125 ≥35 U/mL correctly identifies malignancy in 90% of postmenopausal women with pelvic masses 3
  • Enhanced specificity: When combined with Doppler showing resistive index <0.5, raising the CA-125 cutoff to 65 U/mL achieves 100% specificity and positive predictive value 1
  • Best combination: CA-125 paired with postmenopausal status yields the highest positive likelihood ratio (29.7) for predicting malignancy 5

Practical Algorithm for CA-125 Use

  1. If O-RADS 1-2: CA-125 not needed; lesion is benign
  2. If O-RADS 3: Consider CA-125; if elevated (≥35 U/mL), escalate surveillance or proceed to MRI
  3. If O-RADS 4-5: Obtain CA-125, but do not let a normal value delay referral to gynecologic oncology 2

Role of CEA: Limited Utility

CEA has minimal role in primary ovarian mass evaluation 6. CEA is more relevant for:

  • Mucinous tumors: May be elevated in mucinous ovarian neoplasms
  • Metastatic disease: Helps identify gastrointestinal primary tumors metastatic to the ovary

Do not routinely order CEA for isolated ovarian enlargement unless ultrasound features suggest metastatic disease (bilateral masses, omental involvement) or mucinous characteristics. The evidence shows CA-125 combined with ultrasound provides superior diagnostic accuracy 6, 5.

Management Algorithm

For O-RADS 1-3 Lesions:

  • Simple cysts <5cm: Observation acceptable; no CA-125 needed 1
  • Complex features or elevated CA-125: Obtain MRI with IV contrast for further characterization 1

For O-RADS 4 Lesions:

  • Measure CA-125
  • Consider MRI if diagnosis remains uncertain
  • Refer to gynecologic oncologist if CA-125 elevated or imaging highly suspicious

For O-RADS 5 Lesions:

  • Direct referral to gynecologic oncologist 2
  • Measure CA-125 for surgical planning and staging, not for diagnosis
  • Do not delay referral awaiting tumor marker results

Common Pitfalls to Avoid

  1. Relying on CA-125 alone: Never use CA-125 as a standalone test; it must be interpreted with ultrasound findings 1

  2. Missing transvaginal ultrasound: Transabdominal imaging alone is inadequate for risk assessment 1

  3. Omitting Doppler evaluation: Color/power Doppler is essential to differentiate solid components from debris and identify neovascularity 1

  4. Delaying referral for normal CA-125: A normal CA-125 does NOT exclude malignancy in postmenopausal women with suspicious ultrasound features 2, 1

  5. Ordering CEA routinely: CEA adds minimal value unless specific features suggest mucinous or metastatic disease 6

When to Order MRI

MRI with IV contrast is the next step for indeterminate masses (uncertain organ of origin or unclear benign vs. malignant characterization) 1. MRI achieves:

  • 91% overall accuracy for diagnosing malignancy
  • Superior to CT and Doppler ultrasound for characterizing indeterminate lesions
  • Posttest probability of malignancy: 95% in postmenopausal women with suspicious features 1

Order MRI before surgical referral for O-RADS 3-4 lesions when diagnosis remains uncertain after transvaginal ultrasound with Doppler and CA-125 evaluation 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.